| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.2 | 2.5 |
| Gross profit | 0.2 | 0.9 |
| Net income | -9.8 | -12.7 |
| EPS (diluted, $ a share) | $-0.12 | $-0.17 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -11.1% |
|---|---|
| Gross margin | 10.7% |
| Operating margin | -443.9% |
10-Q filed with the SEC, NASDAQ: NSPR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
InspireMD, Inc.: key numbers
- Share price
- $0.6000Close, Nov 16
- Market cap
- $32.5M
- Shares outstanding
- 54.13MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from InspireMD, Inc.
All →InspireMD Capital Raise of $37.5M
InspireMD, Inc. priced an underwritten public offering of common stock and pre-funded warrants for gross proceeds of approximately $37.5 million. The offering includes 7,342,308 shares of common stock and pre-funded warrants for 50,350,000 shares, each accompanied by Series L warrants. Proceeds are intended for research and development, sales and marketing, and general corporate purposes.
- Value
- $37.5M
- Counterparty
- Lake Street Capital Markets, LLC
InspireMD Financial Results
InspireMD reported third quarter 2026 financial results, highlighted by total revenue of $2.2 million, a 9% increase year-over-year driven by international performance. During the quarter, the company received FDA approval for its CGuard Prime carotid stent system for TCAR procedures, which is expected to double its U.S. addressable market with a commercial launch planned for Q4 2026.
- Term
- Q3 2026
“FDA approval of CGuard Prime for TCAR procedures represents a transformative milestone for InspireMD, enabling the launch of our next-g”
Marvin Slosman, Chief Executive Officer
InspireMD Regulatory Approval
InspireMD received FDA approval for its CGuard Prime TransCarotid Stent System for use in transcarotid artery revascularization (TCAR) procedures. This approval doubles the company's total addressable market in the U.S., providing access to over 35,000 annual procedures with its proprietary MicroNet technology.
InspireMD $11M Debt Financing
InspireMD entered into amendments with holders of its Series J and Series K warrants to align their exercise triggers with the anticipated Q4 2026 FDA approval of the CGuard Prime 80 cm. The amendments modify the exercise price to $0.7674 per share for approximately 14.3 million underlying shares, potentially providing up to $11 million in gross proceeds to fund the product launch. The new expiration date is set for 20 trading days following the announcement of FDA approval or May 15, 2028.
- Value
- $11M